A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Official title

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

Overview

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood cell production. This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA) in adult participants with AML ineligible to receive intensive chemotherapy. Pivekimab sunirine is a drug being evaluated in the treatment of AML.This is a Phase 2/Phase 3, study of PVEK. Phase 2 is open-label and randomized. Phase 3 is double-blind, randomized. Phase 2 and Phase 3 studies test potential new treatments in patients with a condition or disease. Open-label means that both patients and study doctors know which study treatment is given to patients in Phase 2 of the study. Double-blind means that neither the patients nor the study doctors know who is given which study treatment in Phase 3 of the study. Approximately 660 adult participants will be enrolled in 180 sites worldwide. In Phase 2 of the study, patients will be randomized to receive PVEK + VEN + AZA or standard of care treatment with VEN + AZA. In Phase 3, patients will be randomized to receive PVEK + VEN + AZA or a matching-placebo for PVEK plus VEN + AZA. PVEK is given as an infusion into the vein, AZA is given as an injection under your skin (subcutaneous) or as an infusion into the vein (intravenous) (depending on country where patient enrolls), and VEN is a tablet given by mouth. The total study duration is approximately 71 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Interventions

• Drug Pivekimab Sunirine
  Intravenous
• Drug Venetoclax
  Orally
• Drug Azacitidine
  Intravenous Or Subcutaneous
• Drug Matching Placebo for PVEK
  Intravenous

Primary outcome measures

• Phase 2: Complete remission (CR) [Time frame: Up to Approximately 71 Months]
• Phase 3: Complete remission (CR) [Time frame: Up to Approximately 71 Months]
• Phase 3: Overall Survival (OS) [Time frame: Up to Approximately 71 Months]
• Number of Participants with Adverse Events (AEs) [Time frame: Up to approximately 71 months]

Secondary outcome measures (9)

• Phase 2 and Phase 3: Composite Response [Time frame: Up to Approximately 71 Months]
• Phase 2 and Phase 3: Duration of CR (DoCR) [Time frame: Up to Approximately 71 Months]
• Phase 2: Change from baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORCT QLQ-C30) domains [Time frame: Up to Approximately 71 Months]
• Phase 3: Percentage of Participants with Transfusion Independence [Time frame: Up to Approximately 71 Months]
• Phase 3: Conversion from baseline transfusion dependence to post-baseline transfusion independence [Time frame: Up to Approximately 71 Months]
• Phase 3: Change from baseline in the EORCT QLQ-C30 physical functioning domains [Time frame: Up to Approximately 71 Months]
• Phase 3: Change from baseline in the remaining EORCT QLQ-C30 domains [Time frame: Up to Approximately 71 Months]
• Phase 3: Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Utility Index and Visual Analog Scale (VAS) scores [Time frame: Up to Approximately 71 Months]
• Phase 3: Change from Baseline to the responses to FACT GP5 [Time frame: Up to Approximately 71 Months]

Eligibility criteria

Inclusion criteria

• Participants must have newly diagnosed, untreated confirmed acute myeloid leukemia (AML) diagnosis as per the 5th edition of World Health Organization (WHO) criteria with a projected life expectancy of at least 12 weeks.
• CD123-positive
• Ineligible for intensive induction therapy (chemotherapy) defined by:

• ≥ 75 years of age OR
• ≥ 18 to 74 years of age with at least one of the following co-morbidities:

• Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3
• Cardiac history of congestive heart failure requiring treatment or ejection fraction ≤ 50% or chronic stable angina
• Diffusion capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%
• Creatinine clearance ≥ 30 mL/min to < 45 mL/min
• Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × upper limit of normal (ULN)
• Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the medical monitor before study enrollment.
• ECOG performance status 0 to 2 for subjects ≥ 75 years of age or 0 to 3 for subjects ≥ 18 to 74 years of age.
• White blood cell (WBC) count < 25 × 10\^9/L (hydroxyurea is permitted prior to beginning study treatment to reduce the WBC count to < 25 × 10\^9/L).
• Subjects must have adequate organ function:

• Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.
• Adequate liver function as demonstrated by:

• Aspartate aminotransferase (AST) ≤ 3.0 × ULN\*,
• Alanine aminotransferase (ALT) ≤ 3.0 × ULN\*,

---\*Unless considered due to leukemic organ involvement

• Subjects < 75 years of age may have total bilirubin ≤ 3 x ULN
• Subjects ≥ 75 years of age total bilirubin ≤ 1.5 × ULN unless elevated level is considered to be due to Gilbert's syndrome or hemolysis, total bilirubin must be < 3 x ULN and direct bilirubin < 1 x ULN
• Activated partial thromboplastin time (aPTT) and prothrombin time (PT) not to exceed 1.5 × ULN International Normalized Ratio (INR) <1.5

Exclusion criteria

• Acute promyelocytic leukemia (APL), blast phase of CML or AML with t(9;22) or BCR:ABL1 fusion, transformation from myeloproliferative neoplasm (MPN), Chronic Myelomonocytic Leukemia (CMML), myelodysplastic/myeloproliferative neoplasm unspecified, or myeloid sarcoma.
• Known active central nervous system (CNS) involvement with AML. Participants may have non-CNS extramedullary disease (excludes participants with myeloid sarcoma as the only disease manifestation at screening).
• Participants with history of any malignancies within 2 years prior to screening with exception of: adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of the breast, in situ - carcinomas of bladder and esophagus; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, and previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and have no evidence of relapse within 2 years.
• Participants must not have received a hypomethylating agent, any BCL-2 inhibitors including venetoclax, and/or chemotherapeutic agent for Myelodysplastic syndromes (MDS) or AML, CAR-T cell therapy, be currently participating in another clinical study, received any investigational treatment within 30 days prior to the first use of study combination product.
• Female participant must not be pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study and for approximately 7 months after the last dose of any study drug. Female participant of childbearing potential must agree to use at least 1 protocol specified method of birth control and male participant, if sexually active with female partner(s) of childbearing potential, must agree to practice the protocol-specified contraception.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Sequential

Masking

Double blind

Primary purpose

Treatment

Study locations

United States · 4 centers

• Mayo Clinic Hospital - Phoenix /ID# 282904 — Phoenix
• City of Hope National Medical Center /ID# 279568 — Duarte
• Mayo Clinic Hospital Jacksonville /ID# 282903 — Jacksonville
• Montefiore Medical Center - Moses Campus /ID# 279399 — The Bronx

Israel · 4 centers

• Tel Aviv Sourasky Medical Center /ID# 278717 — Tel Aviv
• Rambam Health Care Campus- Haifa /ID# 278719 — Haifa
• Shaare Zedek Medical Center /ID# 278712 — Jerusalem
• Hadassah Medical Center-Hebrew University /ID# 278866 — Jerusalem

Taiwan · 2 centers

• China Medical University Hospital /ID# 279261 — Taichung
• Taichung Veterans General Hospital /ID# 279296 — Taichung

South Korea · 1 center

• Samsung Medical Center /ID# 279397 — Seoul

Identifiers

NCT: NCT07581002 · M26-092 · 2025-523724-47-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗